Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Research topic
No spam. Unsubscribe anytime.
Debate over investigational ibogaine research divides behavioral health leaders and veterans advocates
Summary
HB1772 would authorize investigational clinical research into ibogaine for conditions including PTSD and traumatic brain injury; proponents cited early promising studies and veteran interest, while behavioral health chiefs warned of cardiac risks, psychosis and weak safeguards in the bill’s language.
Representative Mike Moffett opened the hearing on House Bill 1772, saying the measure is intended to allow New Hampshire to participate in sanctioned clinical trials of ibogaine, a Schedule I psychoactive compound touted by some veterans as helpful for PTSD and traumatic brain injury. "Promising breakthrough treatments like ibogaine therapy can help military veterans with PTSD, TBI and other mental health conditions," Moffett said, citing preliminary studies and veteran demand.
Opposition from clinical leaders: Dr. Mindy Asbury, speaking for the Community Behavioral Health Association of New Hampshire, urged the committee to reject HB1772 in its current form. She cited safety concerns, including reports of cardiac arrhythmias and deaths linked to ibogaine, the drug’s long half‑life (detected up to 96 hours), variable effects across patients, and reports of psychosis and worsening mental illness. She warned that vague language allowing “health care prescribers” to authorize investigational use could create loopholes that bypass standard clinical trial safeguards.
Committee discussion: Senators asked about existing evidence and whether deaths tied to ibogaine were reported in controlled settings or overseas; witnesses and committee members noted data are mixed and that clinical safeguards and prescriber qualifications would need clearer statutory guardrails for safe, regulated research. Dr. Asbury recommended stronger conditions (e.g., requiring IRB‑approved trials, defined prescriber qualifications, and medical monitoring) before authorizing investigational use.
Public interest and next steps: Proponents argued enabling regulated research could reduce harms from veterans seeking unregulated treatment abroad; opponents said the bill risks sending a public signal that the state approves safety before the FDA or clinical evidence supports it. The committee closed the hearing; no final vote on HB1772 is recorded in the transcript.
